Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,668.03
(
-0.32%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: linhdtu post# 157225

Thursday, 02/21/2013 8:02:33 PM

Thursday, February 21, 2013 8:02:33 PM

Post# of 257268

AMRN—When I looked into Lovaza patent portfolio on the FDA OB site, Lovaza has only 3 patents listed whereas Vascepa has 8 currently listed and counting related to the Anchor trial.

What matters is not the quantity of patents in the Orange Book, but rather the quality. AMRN’s patents will (IMO) be challenged on the basis of obviousness.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today